Zentalis Pharmaceuticals, Inc. (ZNTL)

USD 2.92

(-6.87%)

Market Cap (In USD)

207.73 Million

Revenue (In USD)

-

Net Income (In USD)

-292.19 Million

Avg. Volume

1.84 Million

Currency
USD
Country
Healthcare
Open
-
Prev. Close
-
Day Range
-
Year Range
2.66-18.07
PE
-
EPS
-
Beta Value
1.742
ISIN
US98943L1070
CUSIP
98943L107
CIK
1725160
Shares
-
Earnings Annoncement
-

Company Profile

Sector
Healthcare
Industry
Biotechnology
CEO
Dr. Kimberly Lynn Blackwell M.D.
Employee Count
-
Website
https://zentalis.com
Ipo Date
2020-04-03
Details
Zentalis Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on discovering and developing small molecule therapeutics for the treatment of various cancers. Its lead product candidate includes the ZN-c3, an inhibitor of WEE1, a protein tyrosine kinase, which is in Phase 2 clinical trial for the treatment of advanced solid tumors; Phase 1/2 clinical trial for the treatment of advanced solid tumors as a monotherapy and in an ongoing Phase 1b clinical trial in combination with chemotherapy in patients with platinum resistant ovarian cancer; and Phase 2 monotherapy trial for a tumor agnostic, predictive biomarker. The company's other lead product candidate includes ZN-c5, an oral selective estrogen receptor degrader that is in a Phase 1/2 clinical trial for the treatment of advanced estrogen receptor-positive, human epidermal growth factor receptor 2-negative, or advanced or metastatic breast cancer. In addition, it is involved in developing ZN-d5, a selective inhibitor of B-cell lymphoma 2 that is in a Phase 1 clinical trial for the treatment of non-Hodgkin's lymphoma and acute myelogenous leukemia; and ZN-e4, an irreversible inhibitor of mutant epidermal growth factor receptor, which is in Phase 1/2 clinical trial for the treatment of advanced non-small cell lung cancer. Further, the company is developing BCL-xL heterobifunctional degraders based on E3 ligases not expressed in platelets, allowing for the avoidance of dose-limiting thrombocytopenia associated with BCL-xL inhibitors. Zentalis Pharmaceuticals, Inc. has licensing agreements and strategic collaborations with Recurium IP Holdings, LLC; Mayo Foundation for Medical Education and Research; SciClone Pharmaceuticals International (Cayman) Development Ltd.; Pfizer, Inc.; Eli Lilly and Company; GlaxoSmithKline, and Zentera Therapeutics (Cayman), Ltd. The company was incorporated in 2014 and is based in New York, New York.